Preventive percutaneous coronary intervention (PCI) or medical therapy alone for vulnerable atherosclerotic coronary plaque: Rationale and design of the randomized, controlled PREVENT trial
Authors' conclusion
The PREVENT trial is the first large-scale, randomized trial to evaluate the effect of preventive PCI on non-flow-limiting vulnerable plaques containing multiple high-risk features that is appropriately powered for clinical outcomes.
Study context
- Population
- Patients with functionally nonsignificant (FFR >0.80) angiographically significant stenosis (>50%) meeting ≥2 intracoronary imaging criteria for vulnerable plaqueenrolment completed
- Participants
- 1,608 patients
- Comparison
- Preventive PCI plus optimal medical therapy (OMT) vs OMT alone
- Primary endpoint
- Target-vessel failure:
- Cardiac death
- Target-vessel MI
- Ischemia-driven target-vessel revascularization or hospitalization for unstable or progressive angina
- Follow-up
- 2 years after randomization
Methodological detailsmultinational, multicentre, prospective, open-label, active-treatment-controlled, 1:1 randomisation
- Multinational
- Multicentre
- Prospective
- Open-label
- Active-treatment-controlled
- 1:1 randomisation
Primary result
As reported in the abstract
- Primary results expected early 2024; follow-up completes September 2023
Original publication
Preventive PCI or medical therapy alone for vulnerable atherosclerotic coronary plaque: Rationale and design of the randomized, controlled PREVENT trial. Am Heart J. Published 2 June 2023. doi:10.
Summarised from the published abstract; every number is checked against it